European Heart Journal-Cardiovascular Pharmacotherapy

Papers
(The TQCC of European Heart Journal-Cardiovascular Pharmacotherapy is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)
ArticleCitations
Comments on—The noradrenaline dosing in the new 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure67
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials59
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study54
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study50
Interdisciplinary recommendations for recurrent hyperkalaemia: Insights from the GUARDIAN-HK European Steering Committee45
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients44
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials42
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor37
Early initiation of SGLT2 inhibitors after acute myocardial infarction35
Current evidence and future perspective for the management of left-sided prosthetic valve thrombosis33
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study31
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia31
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis31
Treatment with dual antiplatelet therapy after an acute coronary event may often be tailor-made for the patient30
Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlle29
Need for more evidence of safety in the pharmacological therapy of anaemia in chronic kidney disease: a cardiovascular perspective29
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study28
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy28
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy27
Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy26
Challenges in cardiovascular pharmacogenomics implementation: a viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy25
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’23
New ways of mitigating aldosterone in cardiorenal disease23
All about clinical trials22
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data22
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis21
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives21
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials21
De-escalation versus shortening of dual antiplatelet therapy20
Cardiovascular prevention and risk factors20
Long-term antiplatelet monotherapy after PCI: searching for the smart choice19
Dosage of direct oral anticoagulants during dual and triple antithrombotic therapy: a focus on the net clinical benefit19
Association of guideline-directed medical therapy adherence with outcomes after fractional flow reserve-based deferral of revascularization19
Late breaking clinical trials at ACC 2219
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis18
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-18
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial17
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic17
News in cardiovascular pharmacotherapy from the ACC.24 Meeting17
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!17
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies16
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry16
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results16
Dronedarone vs. placebo in patients with atrial fibrillation or atrial flutter across a range of renal function: apost hocanalysis of the ATHENA trial16
Entering a new era of antiplatelet therapy: the 4D-ACS trial16
Incidence, associated outcomes, and predictors of upper gastrointestinal bleeding following acute myocardial infarction: a SWEDEHEART-based nationwide cohort study15
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials15
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202315
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis15
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis14
Photoinduced skin reactions of cardiovascular drugs—a systematic review14
Focus on different aspects of atrial fibrillation14
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts14
Are NOACs always the best strategy in elderly AF patients?14
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry13
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes13
Effects of renin–angiotensin system inhibitor type and dosage on survival after transcatheter aortic valve implantation13
What's new in pharmacotherapy at ESC Congress 2023?12
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study12
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis12
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?12
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation12
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202212
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?12
Platelet P2Y12 inhibiting therapy in adjunct to vascular dose of rivaroxaban or aspirin: a pharmacodynamic study of dual pathway inhibition vs. dual antiplatelet therapy11
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue11
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr11
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials11
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis11
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study11
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry11
RNA-targeted therapeutics in cardiovascular disease: the time is now10
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial10
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm10
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study10
FLOW trial stopped early due to evidence of renal protection with semaglutide9
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure9
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial9
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists9
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study9
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark9
Treating patients with anticoagulants and antiplatelet drugs is always a balance between risk for thrombosis vs. risk for bleeding9
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease9
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study9
News in cardiovascular pharmacotherapy from the ACC.25 Meeting8
The role of inotropes in cardiogenic shock: to help, to harm or do nothing at all?8
Response to—Current evidence and future perspective for the management of left sided prosthetic valve thrombosis8
Tolerability and efficacy of sodium-glucose co-transporter 2 inhibitors in patients with cardiac amyloidosis: a meta-analysis of observational studies8
Fenofibrate therapy and risk of heart failure outcomes in patients with Type 2 diabetes: a propensity-matched cohort study8
Cardiovascular risks of continuing vs. initiating NSAIDs after first-time myocardial infarction or heart failure: a nationwide cohort study8
2024 ESC Guidelines for the management of elevated blood pressure and hypertension: what is new in pharmacotherapy?8
The ESC Working Group on cardiovascular pharmacotherapy: continuity through transformation8
Corrigendum to: Association between use of novel glucose-lowering drugs and COVID-19 hospitalization and death in patients with type 2 diabetes: A nationwide registry analysis8
0.052628040313721